TNF and psoriasis: Recently, the systemic administration of biological macromolecular drugs such as antibodies against TNF-α (e.g., infliximab, adalimumab), interleukin-12 (e.g., ustekinumab), and TNF-α receptor fusion protein (e.g., etanercept) have been used to treat psoriasis when traditional topical and systemic therapies do not achieve sufficient responses [87,88].